These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2441 related articles for article (PubMed ID: 28607485)

  • 1. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer.
    Kamerkar S; LeBleu VS; Sugimoto H; Yang S; Ruivo CF; Melo SA; Lee JJ; Kalluri R
    Nature; 2017 Jun; 546(7659):498-503. PubMed ID: 28607485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and testing of clinical-grade exosomes for pancreatic cancer.
    Mendt M; Kamerkar S; Sugimoto H; McAndrews KM; Wu CC; Gagea M; Yang S; Blanko EVR; Peng Q; Ma X; Marszalek JR; Maitra A; Yee C; Rezvani K; Shpall E; LeBleu VS; Kalluri R
    JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.
    Zhao X; Liu L; Lang J; Cheng K; Wang Y; Li X; Shi J; Wang Y; Nie G
    Cancer Lett; 2018 Sep; 431():171-181. PubMed ID: 29870774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic Kras
    McAndrews KM; Xiao F; Chronopoulos A; LeBleu VS; Kugeratski FG; Kalluri R
    Life Sci Alliance; 2021 Sep; 4(9):. PubMed ID: 34282051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitin-binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer.
    Xiong X; Rao G; Roy RV; Zhang Y; Means N; Dey A; Tsaliki M; Saha S; Bhattacharyya S; Dhar Dwivedi SK; Rao CV; McCormick DJ; Dhanasekaran D; Ding K; Gillies E; Zhang M; Yang D; Bhattacharya R; Mukherjee P
    FASEB J; 2020 Sep; 34(9):12024-12039. PubMed ID: 32692445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer.
    Pei Y; Chen L; Huang Y; Wang J; Feng J; Xu M; Chen Y; Song Q; Jiang G; Gu X; Zhang Q; Gao X; Chen J
    Small; 2019 Jun; 15(24):e1900631. PubMed ID: 31033217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical role of oncogenic KRAS in pancreatic cancer (Review).
    Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
    Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zeb1 in Stromal Myofibroblasts Promotes
    Sangrador I; Molero X; Campbell F; Franch-Expósito S; Rovira-Rigau M; Samper E; Domínguez-Fraile M; Fillat C; Castells A; Vaquero EC
    Cancer Res; 2018 May; 78(10):2624-2637. PubMed ID: 29490942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin.
    Chang WH; Nguyen TT; Hsu CH; Bryant KL; Kim HJ; Ying H; Erickson JW; Der CJ; Cerione RA; Antonyak MA
    Cancer Lett; 2021 Oct; 517():66-77. PubMed ID: 34111513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYRI-B-mediated macropinocytosis drives metastasis via lysophosphatidic acid receptor uptake.
    Nikolaou S; Juin A; Whitelaw JA; Paul NR; Fort L; Nixon C; Spence HJ; Bryson S; Machesky LM
    Elife; 2024 May; 13():. PubMed ID: 38712822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
    Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
    J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs.
    Liu H; Sun M; Liu Z; Kong C; Kong W; Ye J; Gong J; Huang DCS; Qian F
    J Control Release; 2019 Feb; 296():40-53. PubMed ID: 30653981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
    Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
    Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.
    Weyandt JD; Lampson BL; Tang S; Mastrodomenico M; Cardona DM; Counter CM
    PLoS One; 2015; 10(10):e0140253. PubMed ID: 26452271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic Lesions.
    Lubeseder-Martellato C; Alexandrow K; Hidalgo-Sastre A; Heid I; Boos SL; Briel T; Schmid RM; Siveke JT
    EBioMedicine; 2017 Feb; 15():90-99. PubMed ID: 28057438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active macropinocytosis induction by stimulation of epidermal growth factor receptor and oncogenic Ras expression potentiates cellular uptake efficacy of exosomes.
    Nakase I; Kobayashi NB; Takatani-Nakase T; Yoshida T
    Sci Rep; 2015 Jun; 5():10300. PubMed ID: 26036864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.
    Huang R; Du H; Cheng L; Zhang P; Meng F; Zhong Z
    Acta Biomater; 2023 Sep; 168():529-539. PubMed ID: 37451658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 123.